Position in ACLX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$42,845,082
New position
Shares Held
373,150
first reported quarter
Ownership
0.638%
of shares outstanding
% of Portfolio
3.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026NEXPOINT ASSET MANAGEMENT, L.P. holds $122,388,926 across 5 Biotechnology names. ACLX ranks #2 (35.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TERN |
Terns Pharmaceuticals, Inc.
|
904,200 | $47,669,423 | |
| 2 | ACLX |
Arcellx, Inc.
This page
|
373,150 | $42,845,082 | |
| 3 | FOLD |
AMICUS THERAPEUTICS, INC.
|
2,039,280 | $29,487,988 | |
| 4 | RNA |
Atrium Therapeutics, Inc.
|
150,025 | $2,005,833 | |
| 5 | HRTX |
Heron Therapeutics, Inc. /De/
|
475,750 | $380,600 |
All Filings in ACLX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $42,845,082 | 373,150 | Shares | Other | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||